Integrated Filing — IndAS



General information about company
Scrip Code 532300
NSE Symbol WOCKPHARMA
MSEI Symbol NA
ISIN INE049B01025
Name of company Wockhardt Limited
Type of company Main Board
Class of security Equity
Date of start of financial year 01-Apr-2024
Date of end of financial year 31-Mar-2025
Date of board meeting when results were approved 29-May-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 23-May-2025
Description of presentation currency INR (in Actuals)
Reporting Type Quarterly
Reporting Quarter Fourth quarter
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Audited
Segment Reporting Single segment
Description of single segment Pharmaceuticals
Start date and time of board meeting 29-May-2025   11:45:00
End date and time of board meeting 29-May-2025   14:45:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Whether the company has any related party? Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. NA
Whether the company is a high value debt listed entity according to regulation 15 (1A)? No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? Yes
Latest Date on which RPT policy is updated 2024-11-13
Indicate Company website link for updated RPT policy of the Company https://www.wockhardt.com/wp-content/uploads/2022/08/prt-31122.pdf
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? Yes
No. of times funds raised during the quarter 2
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
Not Applicable as there is no default on loans and the company has no outstanding debt securities as on 31.03.2025.



Financial Results Ind-AS
Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Jan-2025 01-Apr-2024
B Date of end of reporting period 31-Mar-2025 31-Mar-2025
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
Part I Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.
1 Income
Revenue from operations 3550000000 14020000000
Other income 140000000 550000000
Total income 3690000000 14570000000
2 Expenses
(a) Cost of materials consumed 760000000 3100000000
(b) Purchases of stock-in-trade 440000000 1720000000
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade -350000000 -460000000
(d) Employee benefit expense 640000000 2620000000
(e) Finance costs 400000000 1990000000
(f) Depreciation, depletion and amortisation expense 400000000 1680000000
(f) Other Expenses
1 other expenses 1000000000 4040000000
Total other expenses 1000000000 4040000000
Total expenses 3290000000 14690000000
3 Total profit before exceptional items and tax 400000000 -120000000
4 Exceptional items 0 0
5 Total profit before tax 400000000 -120000000
6 Tax expense
7 Current tax 0 0
8 Deferred tax 0 0
9 Total tax expenses 0 0
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0 0
11 Net Profit Loss for the period from continuing operations 400000000 -120000000
12 Profit (loss) from discontinued operations before tax 0 0
13 Tax expense of discontinued operations 0 0
14 Net profit (loss) from discontinued operation after tax 0 0
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0 0
16 Total profit (loss) for period 400000000 -120000000
17 Other comprehensive income net of taxes 0 -10000000
18 Total Comprehensive Income for the period 400000000 -130000000
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 810000000 810000000
Face value of equity share capital 5 5
27 Details of debt securities
22 Reserves excluding revaluation reserve 26820000000
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 2.47 -0.76
Diluted earnings (loss) per share from continuing operations 2.47 -0.76
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 2.47 -0.76
Diluted earnings (loss) per share from continuing and discontinued operations 2.47 -0.76
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results
Textual Information(1) 1. The results were reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on May 29 , 2025. The Statutory Auditors have expressed an unmodified audit opinion with respect to the Audited Financial Results of the Company for the year ended March 31, 2025. n2. During the quarter ended March 31, 2025 , the Company has allotted 13,250 ( Year to date: 34,860) Equity shares of face value of Rs. 5/- each pursuant to exercise of employee. n3. Further to the approval of the Board of Directors and Shareholders at their meetings, the Company has, on November 11, 2024, alloted 9,049,773 Equity Shares of Rs. 5/- each to Qualified Institutional Buyers at the issue price of Rs.1,105/- per share, aggregating to approximately Rs. 1,000 crore. n4. Figures for the quarter ended March 31, 2025 and March 31, 2024 are the balancing figures between the audited figures of the full financial year and the reviewed figures upto the third quarter of the relevant financial year. n5. The Company is exclusively into Pharmaceutical business segment.



Remarks
Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities
Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-Apr-2024
Date of end of reporting period 31-Mar-2025
Whether results are audited or unaudited Audited
Nature of report standalone or consolidated Standalone
Assets
1 Non-current assets
Property, plant and equipment 12400000000
Capital work-in-progress 790000000
Investment property 0
Goodwill 0
Other intangible assets 360000000
Intangible assets under development 11810000000
Biological assets other than bearer plants 0
Investments accounted for using equity method 0
Non-current financial assets
Non-current investments 2970000000
Trade receivables, non-current 0
Loans, non-current 0
Other non-current financial assets 520000000
Total non-current financial assets 3490000000
Deferred tax assets (net) 2500000000
Other non-current assets 1790000000
Total non-current assets 33140000000
2 Current assets
Inventories 4260000000
Current financial asset
Current investments 4220000000
Trade receivables, current 6120000000
Cash and cash equivalents 350000000
Bank balance other than cash and cash equivalents 780000000
Loans, current 0
Other current financial assets 850000000
Total current financial assets 12320000000
Current tax assets (net) 0
Other current assets 3320000000
Total current assets 19900000000
3 Non-current assets classified as held for sale 1040000000
4 Regulatory deferral account debit balances and related deferred tax Assets 0
Total assets 54080000000
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 810000000
Other equity 26820000000
Total equity attributable to owners of parent 27630000000
Non controlling interest
Total equity 27630000000
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 9370000000
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises 0
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 0
Total Trade payable 0
Other non-current financial liabilities 1950000000
Total non-current financial liabilities 11320000000
Provisions, non-current 300000000
Deferred tax liabilities (net) 0
Deferred government grants, Non-current 0
Other non-current liabilities 0
Total non-current liabilities 11620000000
Current liabilities
Current financial liabilities
Borrowings, current 5900000000
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 470000000
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 4290000000
Total Trade payable 4760000000
Other current financial liabilities 1670000000
Total current financial liabilities 12330000000
Other current liabilities 2180000000
Provisions, current 300000000
Current tax liabilities (Net) 20000000
Deferred government grants, Current 0
Total current liabilities 14830000000
3 Liabilities directly associated with assets in disposal group classified as held for sale
4 Regulatory deferral account credit balances and related deferred tax liability
Total liabilities 26450000000
Total equity and liabilites 54080000000
Disclosure of notes on assets and liabilities Textual Information(1)



Text Block
Textual Information(1) Notes to Assets Liabilities n1. Property, Plant and Equipment of Rs.1240 crore includes Right of use assets amounting to Rs.257 crore. n2. Non-current Investment includes Investments in subsidiaries Rs 297 crore and other invesments Rs. 0.45 crore. n3. Other non-current assets of Rs.179 crore includes Non-current tax assets (net) amounting to Rs. 75 crore. n4. Other non-current financial liabilities consists Lease liabilities amounting to Rs. 195 crore. n5. Other current financial liabilities of Rs. 167 crores include Lease liabilities amounting to Rs. 74 crore. n6. Non-current assets classified as held for sale represents Assets classified as held for sale. nPlease also, additionally refer to the Statement of Standalone Audited Results for the quarter and year ended March 31, 2025 as attached to the Outcome of Board Meeting. n nNotes to Cash Flow Statements: n1. Adjustments for unrealised foreign exchange losses gains consists of Net foreign exchange fluctuation (gain)/Loss, net. n2. Cash inflow (outflow) of cash consists of Margin money under lien and Bank balances (other than cash and cash equivalents) Rs. 41 Crore, Guarantee Commission received Rs. 36 crore and Purchase of current investments (net) Rs. 404 Crore. n3. Proceeds from issuance of shares has been netted off with transaction cost related to right issue/QIP concluded during earlier years of Rs. 1 Crore. This also includes proceeds from issuance of equity Share capital under ESOS Rs 0.02 crore. n4. Proceeds from borrowing amounting to Rs. 430 Crore consists of loan from Related Parties of Rs. 380 Crore. n5.Repayment from borrowing consists of Repayment of long term borrowings Rs. 97 Crore , Repayment of loan taken from Related Parties long term Rs. 333 Crore , Repayment of loan taken from Related Parties Short term Rs. 45 crore and short term borrowing( net ) Rs 288 crore. n6. Decrease in loans and advances and other asset in row no 24 includes decrease in loans and other assets of Rs 167 crores. n7.Other adjustments for non cash items includes Allowance for expected credit loss, doubtful advances and bad debts (net of reversals/recovery) Rs. 9 crore, profit on sale of fixed assets (net) Rs. 3 Crore, Gain on sale of investment Rs. 11 crore and Liabilities no longer required written back Rs. 22 Crore. n8.Aggregated/ segregated in accordance with the prescribed format and to the extent is the requirement of the accounting standard. nPlease also, additionally refer to the Statement of Standalone Audited Results for the quarter and year ended March 31, 2025 as attached to the Outcome of Board Meeting n



Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results
Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-Jan-2025 01-Apr-2024
Date of end of reporting period 31-Mar-2025 31-Mar-2025
Whether accounts are audited or unaudited Audited Audited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income
Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Jan-2025 01-Apr-2024
B Date of end of reporting period 31-Mar-2025 31-Mar-2025
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Items that will not be reclassified to Profit or Loss - charge n(consisting of re-measurement of net defined benefit liability) -1300000 -10000000
2 Income tax relating to items that will not be reclassified to Profit or Loss 0 0
3 Other Comprehensive Income (net of tax) 0 0
4 Rounding off 1300000 0
Total Amount of items that will not be reclassified to profit and loss 0 -10000000
2 Income tax relating to items that will not be reclassified to profit or loss 0 0
3 Amount of items that will be reclassified to profit and loss
Total Amount of items that will be reclassified to profit and loss
4 Income tax relating to items that will be reclassified to profit or loss 0 0
5 Total Other comprehensive income 0 -10000000



Cash flow statement, indirect
Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-Apr-2024
B Date of end of reporting period 31-Mar-2025
C Whether results are audited or unaudited Audited
D Nature of report standalone or consolidated Standalone
Part I Blue color marked fields are non-mandatory.
Statement of cash flows
Cash flows from used in operating activities
Profit before tax -120000000
Adjustments for reconcile profit (loss)
Adjustments for finance costs 1990000000
Adjustments for decrease (increase) in inventories -1050000000
Adjustments for decrease (increase) in trade receivables, current -420000000
Adjustments for decrease (increase) in trade receivables, non-current 0
Adjustments for decrease (increase) in other current assets -1670000000
Adjustments for decrease (increase) in other non-current assets 0
Adjustments for other financial assets, non-current 0
Adjustments for other financial assets, current 0
Adjustments for other bank balances 0
Adjustments for increase (decrease) in trade payables, current -1060000000
Adjustments for increase (decrease) in trade payables, non-current 0
Adjustments for increase (decrease) in other current liabilities 700000000
Adjustments for increase (decrease) in other non-current liabilities 0
Adjustments for depreciation and amortisation expense 1680000000
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0
Adjustments for provisions, current 0
Adjustments for provisions, non-current 0
Adjustments for other financial liabilities, current 0
Adjustments for other financial liabilities, non-current 0
Adjustments for unrealised foreign exchange losses gains -40000000
Adjustments for dividend income 0
Adjustments for interest income 90000000
Adjustments for share-based payments 10000000
Adjustments for fair value losses (gains) -70000000
Adjustments for undistributed profits of associates 0
Other adjustments for which cash effects are investing or financing cash flow 0
Other adjustments to reconcile profit (loss) 0
Other adjustments for non-cash items -270000000
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0
Total adjustments for reconcile profit (loss) -290000000
Net cash flows from (used in) operations -410000000
Dividends received 0
Interest paid 0
Interest received 0
Income taxes paid (refund) -270000000
Other inflows (outflows) of cash 0
Net cash flows from (used in) operating activities -140000000
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0
Cash flows used in obtaining control of subsidiaries or other businesses 0
Other cash receipts from sales of equity or debt instruments of other entities 0
Other cash payments to acquire equity or debt instruments of other entities 0
Other cash receipts from sales of interests in joint ventures 0
Other cash payments to acquire interests in joint ventures 0
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0
Proceeds from sales of property, plant and equipment 100000000
Purchase of property, plant and equipment 410000000
Proceeds from sales of investment property 0
Purchase of investment property 0
Proceeds from sales of intangible assets 0
Purchase of intangible assets 0
Proceeds from sales of intangible assets under development 0
Purchase of intangible assets under development 4630000000
Proceeds from sales of goodwill 0
Purchase of goodwill 0
Proceeds from biological assets other than bearer plants 0
Purchase of biological assets other than bearer plants 0
Proceeds from government grants 0
Proceeds from sales of other long-term assets 0
Purchase of other long-term assets 0
Cash advances and loans made to other parties 0
Cash receipts from repayment of advances and loans made to other parties 0
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0
Dividends received 0
Interest received 30000000
Income taxes paid (refund) 0
Other inflows (outflows) of cash -4090000000
Net cash flows from (used in) investing activities -9000000000
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0
Payments from changes in ownership interests in subsidiaries 0
Proceeds from issuing shares 9820000000
Proceeds from issuing other equity instruments 0
Payments to acquire or redeem entity's shares 0
Payments of other equity instruments 0
Proceeds from exercise of stock options 0
Proceeds from issuing debentures notes bonds etc 0
Proceeds from borrowings 4300000000
Repayments of borrowings 7630000000
Payments of lease liabilities 750000000
Dividends paid 0
Interest paid 0
Income taxes paid (refund) 0
Other inflows (outflows) of cash -880000000
Net cash flows from (used in) financing activities 4860000000
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes -4280000000
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 0
Net increase (decrease) in cash and cash equivalents -4280000000
Cash and cash equivalents cash flow statement at beginning of period 4630000000
Cash and cash equivalents cash flow statement at end of period 350000000





Details of Impact of Audit Qualification
Whether results are audited or unaudited Audited
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results Yes
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto
1 M S K C & Associates LLP Yes 30-Sep-2026


Statement on Deviation or Variation for proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement Etc. (1)
Mode of Fund Raising QIP
Description of mode of fund raising (Applicable in case of others is selected)
Date of Raising Funds 26-Mar-2024
Amount Raised 4800400000
Report filed for Quarter ended 31-Mar-2025
Monitoring Agency Applicable
Monitoring Agency Name, if applicable CRISIL RATINGS LIMITED
Is there a Deviation / Variation in use of funds raised No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders
If Yes, Date of shareholder Approval
Explanation for the Deviation / Variation NA
Comments of the Audit Committee after review NIL
Comments of the auditors, if any NIL
Sr. Original Object Modified Object, if any Original Allocation Modified allocation, if any Funds Utilised Amount of Deviation/Variation for the quarter according to applicable object Remarks if any
1 Repayment and / or pre – payment, in full or part, of certain borrowings availed by the Company. No 1100000000 0 1100000000 0
2 Funding of costs related to the clinical trials and research and development undertaken by the Company and/ or Wockhardt Bio AG, one of the Subsidiaries of the Company No 2100000000 0 2100000000 0
3 Funding working capital requirements of the Company No 1150000000 0 1150000000 0
4 General Corporate Purposes No 278700000 305100000 305100000 0 Net proceeds have been revised from Rs 462.87 crore to Rs 465.51 crore, on account of actual issue expenses being lower than estimated as disclosed in the Placement document, by Rs 2.64 crore and the same has been adjusted with GCP


Statement on Deviation or Variation for proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement Etc. (2)
Mode of Fund Raising QIP
Description of mode of fund raising (Applicable in case of others is selected)
Date of Raising Funds 11-Nov-2024
Amount Raised 10000000000
Report filed for Quarter ended 31-Mar-2025
Monitoring Agency Applicable
Monitoring Agency Name, if applicable CRISIL RATINGS LIMITED
Is there a Deviation / Variation in use of funds raised No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders
If Yes, Date of shareholder Approval
Explanation for the Deviation / Variation NA
Comments of the Audit Committee after review NIL
Comments of the auditors, if any NIL
Sr. Original Object Modified Object, if any Original Allocation Modified allocation, if any Funds Utilised Amount of Deviation/Variation for the quarter according to applicable object Remarks if any
1 Repayment and/or pre-payment, in full or part, of certain borrowings availed by our Company. No 5000000000 0 4163100000 0
2 Funding in capital expenditure, investment in research and development and incidental expenses. No 2500000000 0 152700000 0
3 General Corporate Purpose No 2239700000 0 1127300000 0


Signatory Details
Name of signatory Rashmi Mamtura
Designation of person Company Secretary
Place Mumbai
Date 29-May-2025




Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)
Sr No. Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.
Details of the party (listed entity/subsidiary) entering into the transaction Details of the counterparty Type of related party transaction Details of other related party transaction Value of the related party transaction as approved by the audit committee Remarks on approval by audit committee Value of the related party transaction ratified by the audit committee Date of Audit Committee Meeting where the ratification was approved Value of transaction during the reporting period In case monies are due to either party as a result of the transaction In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments Details of the loans, inter-corporate deposits, advances or investments Notes
Name PAN Name PAN Relationship of the counterparty with the listed entity or its subsidiary Opening balance Closing balance Nature of indebtedness (loan/ issuance of debt/ any other etc.) Details of other indebtedness Cost Tenure Nature (loan/ advance/ intercorporate deposit/ investment ) Interest Rate (%) Tenure Secured/ unsecured Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
1 Wockhardt Limited Wockhardt Bio Ag Subsidiary Any other transaction Purchase of Intellectual Property 42307800000 Approved 2112600000 0 0 Textual Information(1)
2 Wockhardt Limited CP Pharmaceuticals Limited Step down subsidiary Purchase of goods or services 42307800000 Approved 30700000 0 0
3 Wockhardt Limited Wockhardt Bio Ag Subsidiary Sale of goods or services 42307800000 Approved 333600000 0 0
4 Wockhardt Limited CP Pharmaceuticals Limited Step down subsidiary Sale of goods or services 42307800000 Approved 900000 0 0
5 Wockhardt Limited Wockhardt UK Limited Step down subsidiary Sale of goods or services 42307800000 Approved 1600000 0 0
6 Wockhardt Limited Wockhardt USA LLC Step down subsidiary Sale of goods or services 2600000000 Approved 900000 0 0
7 Wockhardt Limited Wockhardt Bio Ag Subsidiary Sale of goods or services 42307800000 Approved 18400000 0 0
8 Wockhardt Limited Pinewood Laboratories Ltd Step down subsidiary Sale of goods or services 42307800000 Approved 2700000 0 0
9 Wockhardt Limited Morton Grove Pharmaceuticals, Inc. Step down subsidiary Sale of goods or services 2600000000 Approved 300000 0 0
10 Wockhardt Limited Wockhardt Bio (R) LLC Step down subsidiary Sale of goods or services 2600000000 Approved 100000 0 0
11 Wockhardt Limited Wockhardt Bio Ag Subsidiary Sale of goods or services 42307800000 Approved 781900000 0 0
12 Wockhardt Limited Wockhardt Bio (R) LLC Step down subsidiary Sale of goods or services 2600000000 Approved 149000000 0 0
13 Wockhardt Limited Wockhardt Infrastructure Development Limited Wholly Owned Subsidiary Purchase of goods or services 0 Not Applicable 80900000 0 0
14 Wockhardt Limited Wockhardt Infrastructure Development Limited Wholly Owned Subsidiary Purchase of goods or services 0 Not Applicable 76100000 0 0
15 Wockhardt Limited Wockhardt Infrastructure Development Limited Wholly Owned Subsidiary Purchase of goods or services 0 Not Applicable 100000 0 0
16 Wockhardt Limited Wockhardt Infrastructure Development Limited Wholly Owned Subsidiary Any other transaction Recovery of Support Service Cost 0 Not Applicable 600000 0 0
17 Wockhardt Limited Wockhardt USA LLC Step down subsidiary Any other transaction Reimbursement received 0 Not Applicable 1400000 0 0
18 Wockhardt Limited Wockhardt UK Limited Step down subsidiary Any other transaction Reimbursement received 0 Not Applicable 10800000 0 0
19 Wockhardt Limited Pinewood Laboratories Ltd Step down subsidiary Any other transaction Reimbursement received 0 Not Applicable 4900000 0 0
20 Wockhardt Limited Wockhardt Bio (R) LLC Step down subsidiary Any other transaction Reimbursement received 0 Not Applicable 200000 0 0
21 Wockhardt Limited Wockhardt Bio Ag Subsidiary Any other transaction Reimbursement paid 0 Not Applicable 15800000 0 0
22 Wockhardt Limited CP Pharmaceuticals Limited Step down subsidiary Any other transaction Reimbursement paid 0 Not Applicable 5700000 0 0
23 Wockhardt Limited Pinewood Laboratories Ltd Step down subsidiary Any other transaction Reimbursement paid 0 Not Applicable 2100000 0 0
24 Wockhardt Limited Wockhardt UK Limited Step down subsidiary Any other transaction Reimbursement paid 0 Not Applicable 2900000 0 0
25 Wockhardt Limited Wockhardt Bio (R) LLC Step down subsidiary Any other transaction Reimbursement paid 0 Not Applicable 6000000 0 0
26 Wockhardt Limited Wockhardt Bio (R) LLC Step down subsidiary Any other transaction Advances Received against Export of Goods 500000000 Approved 111000000 0 0
27 Wockhardt Limited Wockhardt Bio (R) LLC Step down subsidiary Any other transaction Advances adjusted against Export of Goods and Services 500000000 Approved 86100000 0 0
28 Wockhardt Limited Khorakiwala Holdings and Investments Private Limited Enterprises over which Key Managerial Personnel exercise significant influence/control Loan 15000000000 Approved 1828500000 2451000000 2977000000
29 Wockhardt Limited Khorakiwala Holdings and Investments Private Limited Enterprises over which Key Managerial Personnel exercise significant influence/control Any other transaction Loan Repaid 0 Not Applicable 1302500000 0 0
30 Wockhardt Limited Khorakiwala Holdings and Investments Private Limited Enterprises over which Key Managerial Personnel exercise significant influence/control Any other transaction Interest Expense 15000000000 Approved 118700000 479200000 545900000
31 Wockhardt Limited Merind Limited Enterprises over which Key Managerial Personnel exercise significant influence/control Loan 2600000000 Approved 7500000 1339400000 1341600000
32 Wockhardt Limited Merind Limited Enterprises over which Key Managerial Personnel exercise significant influence/control Any other transaction Loan Repaid 0 Not Applicable 5300000 0 0
33 Wockhardt Limited Merind Limited Enterprises over which Key Managerial Personnel exercise significant influence/control Any other transaction Interest Expense 2600000000 Approved 46300000 275300000 312300000
34 Wockhardt Limited Merind Limited Enterprises over which Key Managerial Personnel exercise significant influence/control Any other transaction Recovery of Support Service Cost 1300000 Approved 600000 0 0
35 Wockhardt Limited Themisto Trustee Company Private Limited Enterprises over which Key Managerial Personnel exercise significant influence/control Loan 2600000000 Approved 350000000 400000000 194600000
36 Wockhardt Limited Themisto Trustee Company Private Limited Enterprises over which Key Managerial Personnel exercise significant influence/control Any other transaction Loan Repaid 0 Not Applicable 555400000 0 0
37 Wockhardt Limited Themisto Trustee Company Private Limited Enterprises over which Key Managerial Personnel exercise significant influence/control Any other transaction Interest Expense 2600000000 Approved 41300000 100000 0
38 Wockhardt Limited Ananke Trustee Company Pvt Ltd Enterprises over which Key Managerial Personnel exercise significant influence/control Loan 2600000000 Approved 413400000 2206400000 2206400000
39 Wockhardt Limited Ananke Trustee Company Pvt Ltd Enterprises over which Key Managerial Personnel exercise significant influence/control Any other transaction Loan Repaid 0 Not Applicable 413400000 0 0
40 Wockhardt Limited Ananke Trustee Company Pvt Ltd Enterprises over which Key Managerial Personnel exercise significant influence/control Any other transaction Interest Expense 2600000000 Approved 119500000 377500000 452400000
41 Wockhardt Limited Callirhoe Trustee Company Pvt Ltd Enterprises over which Key Managerial Personnel exercise significant influence/control Loan 2600000000 Approved 50000000 2043200000 1484700000
42 Wockhardt Limited Callirhoe Trustee Company Pvt Ltd Enterprises over which Key Managerial Personnel exercise significant influence/control Any other transaction Loan Repaid 0 Not Applicable 608500000 0 0
43 Wockhardt Limited Callirhoe Trustee Company Pvt Ltd Enterprises over which Key Managerial Personnel exercise significant influence/control Any other transaction Interest Expense 2600000000 Approved 65500000 471800000 520400000
44 Wockhardt Limited Palanpur Holdings and Investments Private Limited Enterprises over which Key Managerial Personnel exercise significant influence/control Loan 2600000000 Approved 684000000 1623800000 1577800000
45 Wockhardt Limited Palanpur Holdings and Investments Private Limited Enterprises over which Key Managerial Personnel exercise significant influence/control Any other transaction Loan Repaid 0 Not Applicable 730000000 0 0
46 Wockhardt Limited Palanpur Holdings and Investments Private Limited Enterprises over which Key Managerial Personnel exercise significant influence/control Any other transaction Interest Expense 2600000000 Approved 83300000 154500000 185800000
47 Wockhardt Limited Carol Info Services Limited Enterprises over which Key Managerial Personnel exercise significant influence/control Purchase of goods or services 2600000000 Approved 431700000 0 0
48 Wockhardt Limited Carol Info Services Limited Enterprises over which Key Managerial Personnel exercise significant influence/control Sale of goods or services 4000000 Approved 2000000 0 0
49 Wockhardt Limited Carol Info Services Limited Enterprises over which Key Managerial Personnel exercise significant influence/control Any other transaction Reimbursement paid 0 Not Applicable 4400000 0 0
50 Wockhardt Limited Dr. Habil Khorakiwala Education and Health Foundation ( Trust) [Wockhardt Global School] Enterprises over which Key Managerial Personnel exercise significant influence/control Any other transaction Recovery of Utility/Infrastructure Fees 50000000 Approved 36800000 0 0
51 Wockhardt Limited Dr. Habil Khorakiwala Education and Health Foundation ( Trust) [Wockhardt Global School] Enterprises over which Key Managerial Personnel exercise significant influence/control Any other transaction Reimbursement paid 0 Not Applicable 17900000 0 0
52 Wockhardt Limited Palanpur Holdings and Investments Private Limited Enterprises over which Key Managerial Personnel exercise significant influence/control Purchase of goods or services 2600000000 Approved 4600000 0 0
53 Wockhardt Limited Palanpur Holdings and Investments Private Limited Enterprises over which Key Managerial Personnel exercise significant influence/control Any other transaction Recovery of Support Service Cost 1300000 Approved 600000 0 0
54 Wockhardt Limited Dr. Habil Khorakiwala Education and Health Foundation ( Trust) Enterprises over which Key Managerial Personnel exercise significant influence/control Any other transaction Rent Income 100000 Approved 0 0 0
55 Wockhardt Limited Enersynk Private Limited Enterprises over which Key Managerial Personnel exercise significant influence/control Purchase of goods or services 5000000 Approved 2400000 0 0
56 Wockhardt Limited Dr. Habil F. Khorakiwala Executive Chairman Remuneration 40000000 Approved 26900000 11600000 14600000
57 Wockhardt Limited Dr. Huzaifa H. Khorakiwala Executive Director Remuneration 28000000 Approved 16700000 3500000 8400000
58 Wockhardt Limited Dr. Murtaza H. Khorakiwala Managing Director Remuneration 28000000 Approved 16700000 3500000 8300000
59 Wockhardt Limited Humuza Consultants Promoter Entity Any other transaction Other Receivables (Balances) 0 Not Applicable 0 1000000 1000000
60 Wockhardt Limited Habil Khorakiwala Trust Promoter Group Entity Any other transaction Other Receivables (Balances) 0 Not Applicable 0 1000000 1000000
61 Wockhardt Limited Wockhardt Hospitals Limited Enterprises over which Key Managerial Personnel exercise significant influence/control Any other transaction Other Receivables (Balances) 0 Not Applicable 0 1000000 1000000
62 Wockhardt Limited Merind Limited Enterprises over which Key Managerial Personnel exercise significant influence/control Any other transaction Other Receivables (Balances) 0 Not Applicable 0 8400000 9100000
63 Wockhardt Limited Carol Info Services Limited Enterprises over which Key Managerial Personnel exercise significant influence/control Any other transaction Security Deposit Given (Balances) 0 Not Applicable 0 555000000 555000000
64 Wockhardt Limited Palanpur Holdings and Investments Private Limited Enterprises over which Key Managerial Personnel exercise significant influence/control Any other transaction Security Deposit Given (Balances) 0 Not Applicable 0 27500000 27500000
65 Wockhardt Limited Wockhardt Regenarative Private Limited Enterprises over which Key Managerial Personnel exercise significant influence/control Any other transaction Other Receivables (Balances) 0 Not Applicable 0 200000 200000
66 Wockhardt Limited Carol Info Services Limited Enterprises over which Key Managerial Personnel exercise significant influence/control Any other transaction Other Receivables (Balances) 0 Not Applicable 0 23800000 9200000
67 Wockhardt Limited Khorakiwala Holdings and Investments Private Limited Enterprises over which Key Managerial Personnel exercise significant influence/control Any other transaction Other Receivables (Balances) 0 Not Applicable 0 20400000 21800000
68 Wockhardt Limited Palanpur Holdings and Investments Private Limited Enterprises over which Key Managerial Personnel exercise significant influence/control Any other transaction Other Receivables (Balances) 0 Not Applicable 0 8400000 9100000
69 Wockhardt Limited Denarius Estate Development Private Limited Enterprises over which Key Managerial Personnel exercise significant influence/control Any other transaction Other Receivables (Balances) 0 Not Applicable 0 1000000 1000000
70 Wockhardt Limited Dr. Habil Khorakiwala Education and Health Foundation (Section 8) Enterprises over which Key Managerial Personnel exercise significant influence/control Any other transaction Other Receivables (Balances) 0 Not Applicable 0 1000000 1000000
71 Wockhardt Limited Adrastea Trading and Services LLP Enterprises over which Key Managerial Personnel exercise significant influence/control Any other transaction Other Receivables (Balances) 0 Not Applicable 0 1000000 1000000
72 Wockhardt Limited Lysithea Consultants Enterprises over which Key Managerial Personnel exercise significant influence/control Any other transaction Other Receivables (Balances) 0 Not Applicable 0 1000000 1000000
73 Wockhardt Limited Lysithea Discretionary Trust Enterprises over which Key Managerial Personnel exercise significant influence/control Any other transaction Other Receivables (Balances) 0 Not Applicable 0 1000000 1000000
74 Wockhardt Limited Themisto Trustee Company Private Limited Enterprises over which Key Managerial Personnel exercise significant influence/control Any other transaction Other Receivables (Balances) 0 Not Applicable 0 1000000 1000000
75 Wockhardt Limited Banneret Trading Private Limited Enterprises over which Key Managerial Personnel exercise significant influence/control Any other transaction Other Receivables (Balances) 0 Not Applicable 0 1000000 1000000
76 Wockhardt Limited HZ Trading and Services LLP Enterprises over which Key Managerial Personnel exercise significant influence/control Any other transaction Other Receivables (Balances) 0 Not Applicable 0 1000000 1000000
77 Wockhardt Limited HNZ Discretionary Trust Enterprises over which Key Managerial Personnel exercise significant influence/control Any other transaction Other Receivables (Balances) 0 Not Applicable 0 1000000 1000000
78 Wockhardt Limited Dartmour Holdings Private Limited Enterprises over which Key Managerial Personnel exercise significant influence/control Any other transaction Other Receivables (Balances) 0 Not Applicable 0 1000000 1000000
79 Wockhardt Limited Amadou Estate Development Private Limited Enterprises over which Key Managerial Personnel exercise significant influence/control Any other transaction Other Receivables (Balances) 0 Not Applicable 0 1000000 1000000
80 Wockhardt Limited Callirhoe Trustee Company Privated Limited Enterprises over which Key Managerial Personnel exercise significant influence/control Any other transaction Other Receivables (Balances) 0 Not Applicable 0 1000000 1000000
81 Wockhardt Limited Shravan Constructions Private Limited Enterprises over which Key Managerial Personnel exercise significant influence/control Any other transaction Other Receivables (Balances) 0 Not Applicable 0 1000000 1000000
82 Wockhardt Limited Holmdene Constructions Enterprises over which Key Managerial Personnel exercise significant influence/control Any other transaction Other Receivables (Balances) 0 Not Applicable 0 1500000 1700000
83 Wockhardt Limited Sharanya Chemicals And Pharmaceuticals Private Limited Enterprises over which Key Managerial Personnel exercise significant influence/control Any other transaction Other Receivables (Balances) 0 Not Applicable 0 1000000 1000000
84 Wockhardt Limited HNZ Trading and Services LLP Enterprises over which Key Managerial Personnel exercise significant influence/control Any other transaction Other Receivables (Balances) 0 Not Applicable 0 1000000 1000000
85 Wockhardt Limited HNZ Consultants Enterprises over which Key Managerial Personnel exercise significant influence/control Any other transaction Other Receivables (Balances) 0 Not Applicable 0 1000000 1000000
86 Wockhardt Limited Khorakiwala Foundation Enterprises over which Key Managerial Personnel exercise significant influence/control Any other transaction Other Receivables (Balances) 0 Not Applicable 0 1000000 1000000
87 Wockhardt Limited Ananke Trustee Company Private Limited Enterprises over which Key Managerial Personnel exercise significant influence/control Any other transaction Other Receivables (Balances) 0 Not Applicable 0 1000000 1000000
88 Wockhardt Limited Pasithee Trustee Company Private Limited Enterprises over which Key Managerial Personnel exercise significant influence/control Any other transaction Other Receivables (Balances) 0 Not Applicable 0 1000000 1000000
89 Wockhardt Limited Megaclite Trading Private Limited Enterprises over which Key Managerial Personnel exercise significant influence/control Any other transaction Other Receivables (Balances) 0 Not Applicable 0 1000000 1000000
90 Wockhardt Limited Genista Trading and Services Private Limited Enterprises over which Key Managerial Personnel exercise significant influence/control Any other transaction Other Receivables (Balances) 0 Not Applicable 0 1000000 1000000
91 Wockhardt Limited Impala Advisory Services Private Limited Enterprises over which Key Managerial Personnel exercise significant influence/control Any other transaction Other Receivables (Balances) 0 Not Applicable 0 1000000 1000000
92 Wockhardt Limited Sinope Advisory Services Private Limited Enterprises over which Key Managerial Personnel exercise significant influence/control Any other transaction Other Receivables (Balances) 0 Not Applicable 0 1000000 1000000
93 Wockhardt Limited Step Forward Advisory Services Private Limited Enterprises over which Key Managerial Personnel exercise significant influence/control Any other transaction Other Receivables (Balances) 0 Not Applicable 0 1000000 1000000
94 Wockhardt Limited Kendo Advisory Services Private Limited Enterprises over which Key Managerial Personnel exercise significant influence/control Any other transaction Other Receivables (Balances) 0 Not Applicable 0 1000000 1000000
95 Wockhardt Limited Lysithea Trading and Services LLP Enterprises over which Key Managerial Personnel exercise significant influence/control Any other transaction Other Receivables (Balances) 0 Not Applicable 0 1000000 1000000
96 Wockhardt Limited Helike Trading and Services LLP Enterprises over which Key Managerial Personnel exercise significant influence/control Any other transaction Other Receivables (Balances) 0 Not Applicable 0 1000000 1000000
97 Wockhardt Limited Amalthea Consultants Enterprises over which Key Managerial Personnel exercise significant influence/control Any other transaction Other Receivables (Balances) 0 Not Applicable 0 1000000 1000000
98 Wockhardt Limited Amalthea Trading and Services LLP Enterprises over which Key Managerial Personnel exercise significant influence/control Any other transaction Other Receivables (Balances) 0 Not Applicable 0 1000000 1000000
99 Wockhardt Limited Amalthea Discretionary Trust Enterprises over which Key Managerial Personnel exercise significant influence/control Any other transaction Other Receivables (Balances) 0 Not Applicable 0 1000000 1000000
100 Wockhardt Limited Dr. Habil Khorakiwala Education and Health Foundation ( Trust) [Wockhardt Global School] Enterprises over which Key Managerial Personnel exercise significant influence/control Any other transaction Other Receivables (Balances) 0 Not Applicable 0 18100000 54800000
101 Wockhardt Limited Wockhardt Foundation Enterprises over which Key Managerial Personnel exercise significant influence/control Any other transaction Other Receivables (Balances) 0 Not Applicable 0 100000 100000
102 Wockhardt Limited Carol Info Services Limited Enterprises over which Key Managerial Personnel exercise significant influence/control Any other transaction Payables (Balances) 0 Not Applicable 0 0 20600000
103 Wockhardt Limited Palanpur Holdings and Investments Private Limited Enterprises over which Key Managerial Personnel exercise significant influence/control Any other transaction Payables (Balances) 0 Not Applicable 0 61300000 66200000
104 Wockhardt Limited Wockhardt Hospitals Limited Enterprises over which Key Managerial Personnel exercise significant influence/control Any other transaction Payables (Balances) 0 Not Applicable 0 6300000 6300000
105 Wockhardt Limited Merind Limited Enterprises over which Key Managerial Personnel exercise significant influence/control Any other transaction Payables (Balances) 0 Not Applicable 0 100000 100000
106 Wockhardt Limited Wockhardt Hospitals Limited Enterprises over which Key Managerial Personnel exercise significant influence/control Any other transaction Receivables (Balances) 0 Not Applicable 0 2600000 2600000
107 Wockhardt Limited Wockhardt Regenarative Private Limited Enterprises over which Key Managerial Personnel exercise significant influence/control Any other transaction Receivables (Balances) 0 Not Applicable 0 9700000 9700000
108 Wockhardt Limited CP Pharmaceuticals Limited Step down subsidiary Any other transaction Receivables (Balances) 0 Not Applicable 0 21800000 19900000
109 Wockhardt Limited Z&Z Services GmbH Step down subsidiary Any other transaction Receivables (Balances) 0 Not Applicable 0 1000000 900000
110 Wockhardt Limited Wockhardt USA LLC Step down subsidiary Any other transaction Receivables (Balances) 0 Not Applicable 0 34700000 38000000
111 Wockhardt Limited Wockhardt Bio Pty Limited Step down subsidiary Any other transaction Receivables (Balances) 0 Not Applicable 0 200000 200000
112 Wockhardt Limited Wockhardt Bio AG Subsidiary Any other transaction Receivables (Balances) 0 Not Applicable 0 4469300000 3651900000
113 Wockhardt Limited Wockhardt UK Limited Step down subsidiary Any other transaction Receivables (Balances) 0 Not Applicable 0 44500000 58300000
114 Wockhardt Limited Pinewood Laboratories Limited Step down subsidiary Any other transaction Receivables (Balances) 0 Not Applicable 0 76600000 83700000
115 Wockhardt Limited Wockhardt Bio (R) LLC Step down subsidiary Any other transaction Receivables (Balances) 0 Not Applicable 0 54700000 52700000
116 Wockhardt Limited Morton Grove Pharmaceuticals Step down subsidiary Any other transaction Receivables (Balances) 0 Not Applicable 0 30300000 31200000
117 Wockhardt Limited Laboratoires Negma S.A.S Step down subsidiary Any other transaction Receivables (Balances) 0 Not Applicable 0 7500000 0
118 Wockhardt Limited Wockhardt Farmaceutica SA DE CV Step down subsidiary Any other transaction Receivables (Balances) 0 Not Applicable 0 62400000 63700000
119 Wockhardt Limited CP Pharmaceuticals Limited Step down subsidiary Any other transaction Payables (Balances) 0 Not Applicable 0 585400000 132600000
120 Wockhardt Limited Wockhardt USA LLC Step down subsidiary Any other transaction Payables (Balances) 0 Not Applicable 0 96900000 98900000
121 Wockhardt Limited Wockhardt Bio AG Subsidiary Any other transaction Payables (Balances) 0 Not Applicable 0 471000000 476400000
122 Wockhardt Limited Wockhardt UK Limited Step down subsidiary Any other transaction Payables (Balances) 0 Not Applicable 0 94200000 59500000
123 Wockhardt Limited Pinewood Laboratories Limited Step down subsidiary Any other transaction Payables (Balances) 0 Not Applicable 0 58200000 59400000
124 Wockhardt Limited Wockhardt Bio (R) LLC Step down subsidiary Any other transaction Payables (Balances) 0 Not Applicable 0 90300000 108500000
125 Wockhardt Limited Morton Grove Pharmaceuticals Step down subsidiary Any other transaction Payables (Balances) 0 Not Applicable 0 33200000 33900000
126 Wockhardt Limited Wockhardt Infrastructure Development Limited Wholly Owned Subsidiary Any other transaction Payables (Balances) 0 Not Applicable 0 1045300000 1133500000
127 Wockhardt Limited CP Pharmaceuticals Limited Step down subsidiary Any other transaction Payables for Capital Goods (Balances) 0 Not Applicable 0 62400000 30200000
128 Wockhardt Limited Pinewood Laboratories Limited Step down subsidiary Any other transaction Payables for Capital Goods (Balances) 0 Not Applicable 0 9600000 9400000
129 Wockhardt Limited Wockhardt Bio AG Subsidiary Any other transaction Payables for Capital Goods (Balances) 0 Not Applicable 0 1173700000 277000000
130 Wockhardt Limited Wockhardt Bio (R) LLC Step down subsidiary Any other transaction Advances from Subsidiaries Against Supply (Balances) 0 Not Applicable 0 44900000 69700000
131 Wockhardt Limited Wockhardt Bio AG Subsidiary Any other transaction Advances from Subsidiaries Against Supply (Balances) 0 Not Applicable 0 167400000 167400000
132 Wockhardt Limited Wockhardt Bio AG Subsidiary Any other transaction Guarantee Fees Receivable (Balances) 0 Not Applicable 0 519900000 411200000
133 Wockhardt Limited Wockhardt Infrastructure Development Limited Wholly Owned Subsidiary Any other transaction Security Deposit Given (Balances) 0 Not Applicable 0 68500000 68500000
134 Wockhardt Limited Morton Grove Pharmaceuticals Step down subsidiary Any other transaction Other Receivables (Expense Recovery Balances) 0 Not Applicable 0 59900000 61100000
135 Wockhardt Limited Wockhardt Infrastructure Development Limited Wholly Owned Subsidiary Any other transaction Other Receivables (Expense Recovery Balances) 0 Not Applicable 0 18400000 19100000
136 Wockhardt Limited Wockhardt Bionova Limited Wholly Owned Subsidiary Any other transaction Other Receivables (Expense Recovery Balances) 0 Not Applicable 0 300000 300000
137 Wockhardt Limited Wockhardt Medicines Limited Wholly Owned Subsidiary Any other transaction Other Receivables (Expense Recovery Balances) 0 Not Applicable 0 600000 600000
138 Wockhardt Limited CP Pharmaceuticals Limited Step down subsidiary Any other transaction Other Liability (Balances) 0 Not Applicable 0 20100000 27200000
139 Wockhardt Infrastructure Development Limited Wockhardt Medicines Limited Fellow Subsidiary Any other transaction Balanaces (Loan) 0 Not Applicable 0 1800000 1800000
140 Wockhardt Infrastructure Development Limited Wockhardt Foundation Enterprises over which Key Managerial Personnel exercise significant influence/control Any other transaction Donation Paid 5000000 Not Applicable 3000000 0 0
141 Wockhardt Bio AG Wockahardt Bio Pty Ltd, Australia Subsidiary Investment 0 Not Applicable 0 600000 700000
142 Wockhardt Bio AG Wockahardt Bio Pty Ltd, Australia Subsidiary Any other transaction Debtors 0 Not Applicable 0 1400000 800000
143 Wockhardt Bio AG Wockahardt Bio Pty Ltd, Australia Subsidiary Any other transaction Advance recceived 0 Not Applicable 0 23900000 29200000
144 Wockhardt Bio AG Wockahardt Bio Pty Ltd, Australia Subsidiary Any other transaction Payables 0 Not Applicable 0 5400000 5300000
145 Wockhardt Bio AG Wockahardt Bio Pty Ltd, Australia Subsidiary Sale of goods or services 3000000000 Approved 600000 0 0
146 Wockhardt Bio AG Z & Z Services GmbH, Germany Subsidiary Loan 0 Not Applicable 0 10600000 11500000
147 Wockhardt Bio AG Z & Z Services GmbH, Germany Subsidiary Loan 0 Not Applicable 0 300000 0
148 Wockhardt Bio AG Wockhardt Europe Limited Fellow Subsidiary Loan 0 Not Applicable 0 97000000 102000000
149 Wockhardt Bio AG CP Pharmaceuticals Limited Subsidiary Investment 0 Not Applicable 0 1233600000 1265000000
150 Wockhardt Bio AG CP Pharmaceuticals Limited Subsidiary Any other transaction Payables 0 Not Applicable 0 2621100000 4001600000
151 Wockhardt Bio AG CP Pharmaceuticals Limited Subsidiary Any other transaction Reimbursement 0 Not Applicable 292900000 0 0
152 Wockhardt Bio AG CP Pharmaceuticals Limited Subsidiary Purchase of goods or services 42307800000 Approved 2306700000 0 0
153 Wockhardt Bio AG Wockhardt Farmaceutica SA DE CV Subsidiary Loan 0 Not Applicable 0 242600000 248700000
154 Wockhardt Bio AG Wockhardt Farmaceutica SA DE CV Subsidiary Any other transaction Debtors 0 Not Applicable 0 1026200000 1052300000
155 Wockhardt Bio AG Wockahrdt USA LLC Step down subsidiary Any other transaction Debtors 0 Not Applicable 0 5796000000 6123000000
156 Wockhardt Bio AG Wockahrdt USA LLC Step down subsidiary Any other transaction Payables 0 Not Applicable 0 69100000 22500000
157 Wockhardt Bio AG Wockahrdt USA LLC Step down subsidiary Sale of goods or services 42307800000 Not Applicable 6800000 0 0
158 Wockhardt Bio AG Wockahrdt UK Limited Subsidiary Investment 0 Not Applicable 0 11200000 11500000
159 Wockhardt Bio AG Wockahrdt UK Limited Subsidiary Any other transaction Payables 0 Not Applicable 0 0 9300000
160 Wockhardt Bio AG Wockahrdt UK Limited Subsidiary Any other transaction Debtors 0 Not Applicable 0 454300000 120800000
161 Wockhardt Bio AG Wockahrdt UK Limited Subsidiary Sale of goods or services 42307800000 Approved 2734000000 0 0
162 Wockhardt Bio AG Wockhardt Bio (R) LLC Subsidiary Investment 0 Not Applicable 0 7200000 7300000
163 Wockhardt Bio AG Wockhardt Bio (R) LLC Subsidiary Any other transaction Payables 0 Not Applicable 0 100000 100000
164 Wockhardt Bio AG Wockpharma Ireland Limited Subsidiary Investment 0 Not Applicable 0 8762700000 8985500000
165 Wockhardt Bio AG Wockpharma Ireland Limited Subsidiary Any other transaction Payables 0 Not Applicable 0 17300000 0
166 Wockhardt Bio AG Pinewood Laboratories Limited Step down subsidiary Any other transaction Debtors 0 Not Applicable 0 1700000 0
167 Wockhardt Bio AG Pinewood Laboratories Limited Step down subsidiary Loan 0 Not Applicable 0 359600000 345100000
168 Wockhardt Bio AG Pinewood Laboratories Limited Step down subsidiary Any other transaction Payables 0 Not Applicable 0 414300000 267500000
169 Wockhardt Bio AG Pinewood Laboratories Limited Step down subsidiary Sale of goods or services 2600000000 Approved 8200000 0 0
170 Wockhardt Bio AG Pinewood Laboratories Limited Step down subsidiary Any other transaction Interest expense 0 Not Applicable 19400000 0 0
171 Wockhardt Bio AG Wockhardt Holding Corp. Subsidiary Investment 0 Not Applicable 0 2748600000 2818500000
172 Wockhardt Bio AG Morton Grove Pharmaceuticals Inc. (consolidated) Step down subsidiary Any other transaction Debtors 0 Not Applicable 0 4700000 4800000
173 Wockhardt Bio AG Morton Grove Pharmaceuticals Inc. (consolidated) Step down subsidiary Any other transaction Payables 0 Not Applicable 0 6340800000 5138600000
174 Wockhardt Bio AG Morton Grove Pharmaceuticals Inc. (consolidated) Step down subsidiary Any other transaction Reimbursement 0 Not Applicable 4600000 0 0
175 CP Pharmaceuticals Limited Wockhardt UK Holdings Limited Fellow Subsidiary Any other transaction Payables 0 Not Applicable 0 769500000 808800000
176 CP Pharmaceuticals Limited Wockhardt UK Holdings Limited (consolidated) Fellow Subsidiary Any other transaction Payables 0 Not Applicable 0 285700000 300300000
177 CP Pharmaceuticals Limited Pinewood Laboratories Limited Fellow Subsidiary Any other transaction Payables 0 Not Applicable 0 164000000 174000000
178 CP Pharmaceuticals Limited Pinewood Laboratories Limited Fellow Subsidiary Purchase of goods or services 3000000000 Approved 248300000 0 0
179 CP Pharmaceuticals Limited Pinewood Laboratories Limited Fellow Subsidiary Any other transaction Advance given 0 Not Applicable 0 24100000 33200000
180 CP Pharmaceuticals Limited Wockahrdt UK Limited Fellow Subsidiary Any other transaction Debtors 0 Not Applicable 0 34600000 76100000
181 CP Pharmaceuticals Limited Wockahrdt UK Limited Fellow Subsidiary Any other transaction Reimbursement received 0 Not Applicable 15100000 0 0
182 Wockhardt UK Holdings Limited (Consolidated) Wockhardt Farmaceutica Do Brasil Ltda Subsidiary Loan 0 Not Applicable 0 14500000 15300000
183 Wockhardt Europe Limited Wockhardt Nigeria Limited Subsidiary Investment 0 Not Applicable 0 4800000 5000000
184 Wockhardt UK Limited Pinewood Laboratories Limited Fellow Subsidiary Any other transaction Debtors 0 Not Applicable 0 1800000 2800000
185 Wockhardt UK Limited Pinewood Laboratories Limited Fellow Subsidiary Any other transaction Debtors 0 Not Applicable 0 5500000 16800000
186 Wockpharma Ireland Limited Pinewood Laboratories Limited Subsidiary Investment 0 Not Applicable 0 9931200000 10165300000
187 Wockpharma Ireland Limited Pinewood Laboratories Limited Subsidiary Any other transaction Payables 0 Not Applicable 0 1610600000 1515300000
188 Morton Grove Pharmaceuticals Inc. (consolidated) Wockahrdt USA LLC Step down subsidiary Loan 0 Not Applicable 0 958600000 983000000
189 Morton Grove Pharmaceuticals Inc. (consolidated) Wockahrdt USA LLC Step down subsidiary Any other transaction Interest expense 0 Not Applicable 19400000 0 0
190 Morton Grove Pharmaceuticals Inc. (consolidated) Wockahrdt USA LLC Subsidiary Investment 0 Not Applicable 0 333700000 342200000
191 Morton Grove Pharmaceuticals Inc. (consolidated) Wockahrdt USA LLC Subsidiary Any other transaction Payables 0 Not Applicable 0 2320400000 774100000
192 Morton Grove Pharmaceuticals Inc. (consolidated) Wockahrdt USA LLC Subsidiary Any other transaction Payables 0 Not Applicable 0 406600000 507600000
193 Wockhardt Farmaceutica SA DE CV Wockhardt Services SA DE CV Fellow Subsidiary Any other transaction Payables 0 Not Applicable 0 85400000 87500000
194 Wockhardt France (Holdings) S.A.S. (consolidated) (liquidated on 07.11.2024) Wockhardt Bio AG Parent Company Loan 0 Not Applicable 0 3915500000 0
195 Wockhardt France (Holdings) S.A.S. (consolidated) (liquidated on 07.11.2024) Wockhardt Bio AG Parent Company Any other transaction Interest Payable 0 Not Applicable 0 195300000 0
196 Wockhardt Service SA DE CV Wockhardt Bio AG Parent Company Any other transaction Payables 0 Not Applicable 0 39200000 40200000
197 Wockhardt UK Holdings Limited (consolidated) CP Pharmaceuticals Limited Fellow subsidiary Any other transaction Payables 0 Not Applicable 0 6300000 6700000
198 Wockhardt Limited Holmdene Constructions Enterprises over which Key Managerial Personnel exercise significant influence/control Any other transaction Recovery of Support Cost 500000 Approved 100000 0 0
199 Wockhardt Limited Carol Info Services Limited Enterprises over which Key Managerial Personnel exercise significant influence/control Any other transaction Reimbursement of Cost 0 Not Applicable 14500000 0 0
200 Wockhardt Limited Laboratoires Negma S.A.S Step down subsidiary Any other transaction Amount no more recoverbale written off 0 Not Applicable 7400000 0 0
Total value of transaction during the reporting period 17502700000



Text Block
Textual Information(1) 1. Differences in the opening and closing balances may be reflected due to Fluctuations in the Exchange Rate. Please note exchange rate as considered below: a. For Opening balance Exchange Rate is considered as on October 01, 2024. b. For Closing balance Exchange Rate is considered as on March 31, 2025. c. For the value of transactions during the period, Average Exchange Rate is considered. 2. The values displayed as 0.00 represents amount less than Rs. 50,000. 3. The value of the related party transaction approved by the audit committee is shown as '0' which does not required approval of Audit Committee as per SEBI LODR Regulations, 2015.